Ruxolitinib, a selective JAK1/2 inhibitor, enhances replication and efficacy of VSV-IFN-β and VSV-ΔM51 in non-small cell lung cancer (NSCLC) and human PDACs, respectively, by inhibiting STAT1/2 phosphorylation and reducing antiviral responses that restrict viral replication (167, 168). The gene discussed is STAT1; the disease is non-small cell lung carcinoma.